Taken altogether, the distinction between HER2-low, HER2-positive, and HER2-negative tumors can be made by immunohistochemical evaluation in clinical practice, and this is the most crucial message for the future of breast cancer diagnosis. This evidence concerns the gene ERBB2 and breast carcinoma.